Ex vivo antibody production

An in vitro, anti-apoptotic technology, applied in the fields of molecular biology, immunology, and medicine, it can solve the problem that antibodies cannot be produced in advance.

Pending Publication Date: 2016-10-12
科凌生物医疗有限公司
View PDF4 Cites 0 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

The above-mentioned antibodies specific to individual tumors cannot be produced in advance

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Ex vivo antibody production
  • Ex vivo antibody production
  • Ex vivo antibody production

Examples

Experimental program
Comparison scheme
Effect test

Embodiment 1

[0111] Transduction of B cells

[0112] Gene transfer into lymphocytes by traditional methods, such as calcium phosphate precipitation, liposome formation, or electroporation, is inefficient but, more importantly, often lacks stable gene integration. However, if an appropriate viral envelope is selected, viral transduction leads directly to the stable integration of the gene into the genome of the target cell, and with very high efficiency. Both retroviral and lentiviral transduction are suitable for efficient gene transfer. While retroviral integration is dependent on cell division, lentiviral transduction can also be used in cells that do not divide, such as plasma B cells. Large-scale production of recombinant retroviruses can be readily achieved using stable producer cell lines such as the Phoenix expression platform (Kinsella and Nolan, 1996). Production of high-titer lentiviruses tends to be more tedious, mainly because of the toxicity of the expressed viral proteins a...

Embodiment 2

[0118] cell culture

[0119] We will B cells (2 × 10 5Cells / ml) were maintained in Iscove's modified Dulbecco's medium (Iscove's modified Dulbecco's medium, Gibco), and they were cultured in γ-irradiated (50Gy) mouse L cell fibroblasts stably expressing CD40L (CD40L-L cells, 10 5 cells / ml). To determine the doubling time of cells, cells were cultured in 24-well plates at a density of 50-100.000 cells / well together with CD40L-L cells and IL-21. Cells were counted every 3-4 days and 50-100.000 cells were transferred to new wells. figure 2 In , B cells from two human donors (89 and 93), a sample of rhea B cells (Rhinosaurus), and a sample of rabbit B cells transduced with a GALV-type retrovirus (Rb 6XL) are shown. Growth curve, the GALV-type retrovirus carries nucleic acid molecules containing human Bcl-6 sequence and human Bcl-xL. In addition, a growth curve of a rabbit sample (Rb6M) transduced with a GALV-type retrovirus carrying a nucleic acid molecule containing the seq...

Embodiment 3

[0121] Expression of B cell receptors and antigen-specific staining

[0122] Immortalized human B cells express the B cell receptor. This property enables antigen-specific staining and sorting of B cells. To determine whether B cell receptors are also expressed on transduced rabbit B cells, B cell clones were stained with fluorescently labeled antibodies that react specifically with rabbit IgG, rabbit IgM, or rabbit IgA. B cells were washed in cold (4°C) cell culture medium and incubated on ice in the dark with immunofluorescence-conjugated antibodies against rabbit IgG, IgM, IgA or markers The antigen is specific. Afterwards, excess labeled antibody or antigen was washed away, and B cell receptor expression was analyzed on a FACS analyzer (Guava easycyte (Millipore) or FACS Aria3 (BD)).

[0123] image 3 In , three different B cell clones of different isotypes were stained using fluorescently-labeled antibodies that specifically recognize rabbit antibody isotypes IgG, IgA...

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to view more

PUM

No PUM Login to view more

Abstract

The present invention provides means and methods for producing improved ex vivo B cell cultures with a short doubling time.

Description

technical field [0001] The present invention relates to the fields of medicine, molecular biology and immunology. Background technique [0002] Ex vivo B cell cultures are an important tool for the production of antibodies, preferably monoclonal antibodies. Monoclonal antibodies (mAbs) represent multiple identical copies of an antibody molecule that bind antigen with the same affinity and promote the same effector function. Among the benefits of mAbs is their specificity for the same epitope on the antigen. This specificity confers on mAbs specific clinical advantages compared to other conventional treatments, while conferring an effective and well-tolerated treatment option for patients, often with low side effects. In addition, mAbs can be used in biological and medical research. [0003] The conventional route to mAbs is the hybridoma technology, in which B cells are fused with myeloma cells to form a hybrid antibody-producing cell line (hybridoma). However, hybridoma...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to view more

Application Information

Patent Timeline
no application Login to view more
Patent Type & Authority Applications(China)
IPC IPC(8): C12N5/0781C07K16/00C12N15/867
CPCC07K16/00C12N2510/00C12N2510/02C12N2510/04C12N15/86C12N2740/13045C12N2810/6054C07K16/1018C12N5/0635C07K2317/14C12P21/005
Inventor 保利娜·玛丽亚·威尔荷米娜·范赫尔登M·J·克瓦肯博斯H·斯皮茨T·博蒙特
Owner 科凌生物医疗有限公司
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Try Eureka
PatSnap group products

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic.

© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap